S Yaccoby

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. pmc Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 5:e15233. 2010
  2. pmc Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
    S Yaccoby
    Myeloma Institute for Research and Therapy, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 22:406-13. 2008
  3. pmc Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 776, Little Rock, AR 72205, USA
    Haematologica 91:192-9. 2006
  4. pmc The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Cancer Res 11:7599-606. 2005
  5. pmc Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2106-11. 2007
  6. ncbi request reprint Cancer and the microenvironment: myeloma-osteoclast interactions as a model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR 72205, USA
    Cancer Res 64:2016-23. 2004
  7. pmc Osteoblastogenesis and tumor growth in myeloma
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leuk Lymphoma 51:213-20. 2010
  8. ncbi request reprint Antimyeloma efficacy of thalidomide in the SCID-hu model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 100:4162-8. 2002
  9. pmc Advances in the understanding of myeloma bone disease and tumour growth
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 149:311-21. 2010
  10. pmc Role of decorin in the antimyeloma effects of osteoblasts
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:159-68. 2008

Research Grants

  1. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2010
  2. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2002
  3. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2003
  4. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2004
  5. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2005
  6. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2009
  7. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2009
  8. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2011

Detail Information

Publications37

  1. pmc Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 5:e15233. 2010
    ..Current management of myeloma bone disease is limited to the use of antiresorptive agents such as bisphosphonates...
  2. pmc Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
    S Yaccoby
    Myeloma Institute for Research and Therapy, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 22:406-13. 2008
    ..Our findings suggest that APRIL plays an essential role in the survival of TACI(high) bone marrow-dependent myeloma cells and TACI gene expression may be a useful predictive marker for patients who could benefit from atacicept treatment...
  3. pmc Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 776, Little Rock, AR 72205, USA
    Haematologica 91:192-9. 2006
    ..Whereas those studies focused on the critical role of myeloma-induced osteoclastogenesis in disease progression, little is known about the impact of osteoblasts and increased bone formation on MM...
  4. pmc The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Cancer Res 11:7599-606. 2005
    ..The aim of the current study was to investigate osteoclast-induced phenotypic changes associated with long-term survival of myeloma cells in coculture...
  5. pmc Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2106-11. 2007
    ..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth...
  6. ncbi request reprint Cancer and the microenvironment: myeloma-osteoclast interactions as a model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR 72205, USA
    Cancer Res 64:2016-23. 2004
    ..These results support data obtained from animal models and clinical observations on the essential role of the microenvironment in tumor sustenance and progression...
  7. pmc Osteoblastogenesis and tumor growth in myeloma
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leuk Lymphoma 51:213-20. 2010
    ....
  8. ncbi request reprint Antimyeloma efficacy of thalidomide in the SCID-hu model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 100:4162-8. 2002
    ....
  9. pmc Advances in the understanding of myeloma bone disease and tumour growth
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 149:311-21. 2010
    ..Unravelling mechanisms of myeloma bone disease expands horizons for developing novel interventions and also facilitates better understanding of the association between induction of osteolysis and disease progression...
  10. pmc Role of decorin in the antimyeloma effects of osteoblasts
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:159-68. 2008
    ....
  11. pmc Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
    Lijuan Chen
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 115:61-70. 2010
    ..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib...
  12. pmc Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 145:775-87. 2009
    ..These data demonstrated that DASH proteases are involved in myeloma bone disease and tumour growth...
  13. ncbi request reprint Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
    Yun Ge
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 133:83-92. 2006
    ..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma...
  14. pmc The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Hematol 84:6-14. 2009
    ....
  15. pmc The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
    Simona Colla
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 109:4470-7. 2007
    ..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression...
  16. ncbi request reprint Soluble syndecan-1 promotes growth of myeloma tumors in vivo
    Yang Yang
    Arkansas Cancer Research Center, Department of Pathology, and the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 100:610-7. 2002
    ..Thus, high levels of soluble syndecan-1 present in patients with myeloma may contribute directly to the growth and dissemination of the malignant cells and thus to poor prognosis...
  17. ncbi request reprint Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins
    M Børset
    Arkansas Cancer Research Center and Departments of Pathology and Anatomy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 96:2528-36. 2000
    ..These data indicate that syndecan-1 is targeted to the uropod of polarized myeloma cells and that this targeting plays a role in promoting cell-cell adhesion and may also regulate the biological activity of heparin-binding cytokines...
  18. ncbi request reprint The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells
    K Yata
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 18:1891-7. 2004
    ..This system can now be widely used to study the biology of myeloma and its manifestations and to develop novel therapeutic approaches for this disease...
  19. pmc The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:1803-12. 2009
    ..Myeloma cells expressed low to undetectable ephrinB2 and EphB4 and did not respond to the chimeric proteins. The ephrinB2/EphB4 axis is dysregulated in MM, and its activation by EphB4-Fc inhibits myeloma growth and bone disease...
  20. ncbi request reprint Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
    Shmuel Yaccoby
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:278-90. 2002
    ..Breaking this loop may help control myeloma...
  21. pmc Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:802-11. 2007
    ..These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy...
  22. doi request reprint Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma
    Erming Tian
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Mol Cancer Ther 7:500-9. 2008
    ..Collectively, our data suggest that EPED3 targets mitochondrial function to rapidly deplete chemical energy and initiate apoptosis in myeloma cells at nanomolar concentrations while leaving stromal cells unharmed...
  23. ncbi request reprint The SCID-hu myeloma model
    Joshua Epstein
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Science, Little Rock, AK, USA
    Methods Mol Med 113:183-90. 2005
    ..This chapter describes in detail all the steps necessary to establish this model and evaluate its success...
  24. pmc Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Cancer Lett 284:175-81. 2009
    ..4HPR is a potential anti-MM agent, affecting MM cells and MM-induced bone disease and angiogenesis...
  25. ncbi request reprint Consequences of interactions between the bone marrow stroma and myeloma
    Joshua Epstein
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Hematol J 4:310-4. 2003
    ....
  26. ncbi request reprint Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 131:71-3. 2005
    ..The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation...
  27. pmc Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 77205, USA
    Blood 112:374-82. 2008
    ..These results provide further support of the potential anabolic and anti-MM effects of enhancing Wnt signaling in the bone...
  28. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    ..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
  29. ncbi request reprint Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Am J Hematol 82:831-3. 2007
    ..01). Markers of osteoblastic activation may predict quality and duration of response in multiple myeloma. In addition, our data suggest that bone anabolism could inhibit myeloma growth...
  30. pmc Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent
    Dan Jia
    Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR72205, USA
    Radiat Res 173:809-17. 2010
    ..These results suggest that radiotherapy, when primed by anti-angiogenic agents, may be a potent therapy for focal multiple myeloma...
  31. ncbi request reprint Response to bortezomib and activation of osteoblasts in multiple myeloma
    Maurizio Zangari
    University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Lymphoma Myeloma 7:109-14. 2006
    ..0001). This clinical observation has been confirmed in an experimental mouse model for primary human myeloma. The consequences of increased bone anabolism on myeloma growth need to be closely evaluated in prospective trials...
  32. pmc Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009
    ....
  33. ncbi request reprint Heparanase promotes the spontaneous metastasis of myeloma cells to bone
    Yang Yang
    Department of Pathology, Myeloma Institute for Research and Therapy, Center for Orthopaedic Research, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 105:1303-9. 2005
    ..These studies describe a novel experimental animal model for examining the spontaneous metastasis of bone-homing tumors and indicate that heparanase is a critical determinant of myeloma dissemination and growth in vivo...
  34. ncbi request reprint Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications
    Ronald Walker
    Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 25:1121-8. 2007
    ..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)...
  35. pmc Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3122-5. 2008
    ..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382...
  36. pmc The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
    Yang Yang
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Blood 110:2041-8. 2007
    ....
  37. ncbi request reprint Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 10:295-307. 2006
    ..Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies...

Research Grants9

  1. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2010
    ....
  2. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2002
    ..This study will help develop an effective treatment for patients with MM or at risk of it, as well as its prevention. ..
  3. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2003
    ..This study will help develop an effective treatment for patients with MM or at risk of it, as well as its prevention. ..
  4. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2004
    ..This study will help develop an effective treatment for patients with MM or at risk of it, as well as its prevention. ..
  5. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2005
    ..This study will help develop an effective treatment for patients with MM or at risk of it, as well as its prevention. ..
  6. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2009
    ....
  7. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2009
    ....
  8. Myeloma-Microenvironment Interaction Dynamics
    Shmuel Yaccoby; Fiscal Year: 2011
    ....